 |
Notes to Editors |
 |
About Archimedes Pharma
Archimedes Pharma is a pharmaceutical company marketing an
expanding portfolio of products to specialist prescribers
in major European territories whilst building a platform
for its future growth through the development of a high-value
pipeline from its world-class drug delivery technologies.
Archimedes’ strategy is to expand its current European
commercial presence through partnering and acquisition. It
is also building a robust pipeline of in-house products in
pain, Parkinson’s disease and critical care by applying
its drug delivery technologies to proven molecules which
have yet to achieve their market potential due to their current
mode of delivery. Archimedes’ lead product, NasalFent®,
intranasal fentanyl for rapid relief of breakthrough cancer
pain, is in Phase III clinical development. This product,
which has blockbuster potential, is targeted for launch in
2009.
Archimedes’ drug delivery
technologies - ChiSys®,
PecSys™ and TARGIT® - are also used in
a number of partnered products in late-stage clinical development.
Additionally, Archimedes’ innovative drug delivery
technology has proven potential for vaccine delivery, with
pre-clinical and clinical studies of nasally administered
vaccines demonstrating enhanced immune response.
Archimedes’ marketed products include
Gliadel, a biodegradable wafer impregnated with an anti-cancer
drug, carmustine, for high-grade glioma; Zomorph, an oral
sustained release morphine product for pain; Nozinan, a
neuroleptic used in psychiatry and as a supportive therapy
for cancer patients; and Pabrinex, a high potency vitamin
formulation used to treat the symptoms of malnutrition,
especially in patients with acute alcohol problems.
Archimedes Pharma is based in Reading, UK and has development
facilities in Nottingham, UK. The Company was founded in December
2004 and is backed by Warburg Pincus, a leading private equity
investor with extensive experience in the healthcare sector.
In 2007 Archimedes had sales of US$40 million.
About Archimedes Development Limited
Archimedes
Development Limited (ADL) is a subsidiary of Archimedes Pharma
Ltd, a fast growing pharmaceutical company focused on meeting
the needs of specialist prescribers in Europe. ADL is focused
on partnering with companies that have compounds which could
benefit from ADL’s suite
of world-class drug delivery technologies. These comprise
two cutting intra-nasal delivery technologies ChiSys® and
PecSys™ as well as TARGIT® which is designed to
deliver drugs to precise regions of the large intestine.
These technologies are able to optimise the profile of a
wide range of drugs by allowing targeted or controlled release.
ADL’s world-class drug delivery technologies
have been validated in a series of partnerships with pharmaceutical
and biotechnology companies. ADL has a flexible approach
to its partnering activities and can apply its technologies
to both existing and new therapeutic products.
ADL currently has development deals in
place with a range of companies. ADL’s transmucosal enhancement technology
ChiSys® is being used by Javelin Pharmaceuticals for
its nasally-delivered morphine product, Rylomine™*
and PecSys™, a novel pectin-based nasal drug delivery
technology designed to maximise the potential of systemically
absorbed drugs by enhancing drug performance and improving
patient acceptance is also being used in other development
deals.
ADL also has a co-development and commercialisation agreement
with Pharmalink AB under which the two parties are developing
a TARGIT® formulation for an anti-inflammatory product
candidate. The TARGIT® technology is also licensed to
Invapharm for specific drug candidates for various indications.
* Rylomine is a trademark of Javelin
back |
